OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
7071$363.0055

Amvis Holdings Inc

Healthcare Facilities & ServicesVerified

Amvis Holdings Inc maintains a capital structure with a debt-to-equity ratio of 1.11, indicating a moderate reliance on debt financing. The company's liquidity position is characterized by a current ratio of 1.12, suggesting it has sufficient short-term assets to cover its short-term liabilities. However, the company's free cash flow is negative at -4.385 billion JPY, which may signal potential liquidity constraints in the near term. In terms of profitability, Amvis Holdings Inc reports a return on equity (ROE) of 10.13% and a return on assets (ROA) of 4.36%. These figures are in line with the industry's preferred metrics, which emphasize ROE and ROA as key indicators of financial performance. The company's net income of 3.66 billion JPY and operating income of 5.504 billion JPY reflect a solid operational performance, although the gross profit margin of 30.08% (14.789 billion JPY on 49.174 billion JPY revenue) suggests there is room for improvement in cost management. Geographically, Amvis Holdings Inc's revenue is concentrated in Japan, as indicated by the JPY-based financials. The company does not disclose specific segment revenues, but its primary business activity is in pharmaceuticals. This concentration may expose the company to regional economic and regulatory risks, particularly in the healthcare sector. The company's growth trajectory is modest, with no specific numeric deltas provided for the current or next fiscal year. However, the capital expenditure of -10.424 billion JPY indicates a significant investment in long-term assets, which could support future growth. The company's operating cash flow of 6.026 billion JPY provides a buffer for these investments and ongoing operations. Risk factors for Amvis Holdings Inc include a medium liquidity risk, as highlighted by the negative net cash position after subtracting total debt. The company's dilution risk is assessed as low, with no significant dilution potential identified in the basic shares outstanding. The risk assessment also notes that the company's liquidity position is a key flag, which may require monitoring in the coming periods. Recent events and filings for Amvis Holdings Inc do not include specific details in the provided data. However, the company's financial statements and disclosures are available for further review. The absence of recent significant events or transcripts does not imply a lack of activity but rather a need to consult additional sources for the most up-to-date information.

30-day price · 7071-57.00 (-13.5%)
Low$335.00High$433.00Close$366.00As of28 May, 00:00 UTC
Profile
CompanyAmvis Holdings Inc
Ticker7071.T
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. Amvis Holdings Inc operates in the healthcare sector, primarily engaged in pharmaceuticals, and generates revenue through the provision of healthcare services and equipment.

Classification. Amvis Holdings Inc is classified under the Healthcare Facilities & Services industry within the Healthcare Services & Equipment business sector, with a classification confidence of 0.92.

Amvis Holdings Inc maintains a capital structure with a debt-to-equity ratio of 1.11, indicating a moderate reliance on debt financing. The company's liquidity position is characterized by a current ratio of 1.12, suggesting it has sufficient short-term assets to cover its short-term liabilities. However, the company's free cash flow is negative at -4.385 billion JPY, which may signal potential liquidity constraints in the near term. In terms of profitability, Amvis Holdings Inc reports a return on equity (ROE) of 10.13% and a return on assets (ROA) of 4.36%. These figures are in line with the industry's preferred metrics, which emphasize ROE and ROA as key indicators of financial performance. The company's net income of 3.66 billion JPY and operating income of 5.504 billion JPY reflect a solid operational performance, although the gross profit margin of 30.08% (14.789 billion JPY on 49.174 billion JPY revenue) suggests there is room for improvement in cost management. Geographically, Amvis Holdings Inc's revenue is concentrated in Japan, as indicated by the JPY-based financials. The company does not disclose specific segment revenues, but its primary business activity is in pharmaceuticals. This concentration may expose the company to regional economic and regulatory risks, particularly in the healthcare sector. The company's growth trajectory is modest, with no specific numeric deltas provided for the current or next fiscal year. However, the capital expenditure of -10.424 billion JPY indicates a significant investment in long-term assets, which could support future growth. The company's operating cash flow of 6.026 billion JPY provides a buffer for these investments and ongoing operations. Risk factors for Amvis Holdings Inc include a medium liquidity risk, as highlighted by the negative net cash position after subtracting total debt. The company's dilution risk is assessed as low, with no significant dilution potential identified in the basic shares outstanding. The risk assessment also notes that the company's liquidity position is a key flag, which may require monitoring in the coming periods. Recent events and filings for Amvis Holdings Inc do not include specific details in the provided data. However, the company's financial statements and disclosures are available for further review. The absence of recent significant events or transcripts does not imply a lack of activity but rather a need to consult additional sources for the most up-to-date information.
Key takeaways
  • Amvis Holdings Inc has a moderate debt-to-equity ratio of 1.11, indicating a balanced capital structure.
  • The company's ROE of 10.13% and ROA of 4.36% suggest strong profitability relative to its equity and assets.
  • The company's free cash flow is negative, which may impact its liquidity and ability to fund operations and investments.
  • Amvis Holdings Inc's revenue is concentrated in Japan, exposing it to regional economic and regulatory risks.
  • The company's liquidity risk is medium, with a negative net cash position after subtracting total debt.
  • The company's dilution risk is low, with no significant dilution potential identified in the basic shares outstanding.
  • --
  • ## RATIONALES
Financial snapshot
PeriodHA-latest
CurrencyJPY
Revenue$49.17B
Gross profit$14.79B
Operating income$5.50B
Net income$3.66B
R&D
SG&A
D&A
SBC
Operating cash flow$6.03B
CapEx-$10.42B
Free cash flow-$4.38B
Total assets$83.95B
Total liabilities$47.81B
Total equity$36.13B
Cash & equivalents$10.83B
Long-term debt$40.15B
Valuation
Market price$363.00
Market cap$35.61B
Enterprise value$64.93B
P/E9.7
Reported non-GAAP P/E
EV/Revenue1.3
EV/Op income11.8
EV/OCF10.8
P/B1.0
P/Tangible book1.0
Tangible book$36.13B
Net cash-$29.32B
Current ratio1.1
Debt/Equity1.1
ROA4.4%
ROE10.1%
Cash conversion1.6%
CapEx/Revenue-21.2%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals · cohort 779 companies
Metric7071Activity
Op margin11.2%7.7% medp25 -2.4% · p75 15.5%above median
Net margin7.4%5.9% medp25 -3.8% · p75 12.8%above median
Gross margin30.1%45.5% medp25 31.1% · p75 62.9%bottom quartile
R&D / revenue529.2% medp25 465.2% · p75 593.2%
CapEx / revenue-21.2%-7.0% medp25 -14.9% · p75 -3.2%bottom quartile
Debt / equity111.0%25.0% medp25 3.8% · p75 63.3%top quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod financials
no public URL
2026-05-19 12:45 UTC#26c1e2e2
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 02:46 UTCJob: 7ef0acb0